Overview of COVID-19 Therapeutics and Prophylaxis for Non-Hospitalized Patients

The resources below provide:
  1. Interim guidance on outpatient treatment decisions for patients at risk of developing severe COVID-19.
  2. Comparison table of treatment options.

Treatment

*Adapted from COCA call 1/22/22
Clinicians should refer to the EUA healthcare provider fact sheets for further details on paxlovidremdesivir, and molnupiravir. For the FDA-approved remdesivir (Veklury) for 12 yrs and older weight at least 40kg, refer to the full prescribing information.

Prophylaxis

There are currently no authorized prophylactic treatments for COVID-19.
Evusheld
Description
  • Evusheld is a monoclonal antibody combination approved for use as a Pre-exposure Prophylaxis for those who are unable to receive or are not expected to mount an immune response with vaccines.
  • Distribution should be prioritized to hospitals that offer special services such as oncology and rheumatology, etc. Providers who care for such patients should refer to these centers for access to this product.
Patient Profiles
  • Active treatment for solid tumor and hematologic malignancies
  • Receipt of solid-organ transplant and taking immunosuppressive therapy
  • Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within two years of transplantation or taking immunosuppression therapy)
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
  • Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents).

Locate Therapeutics and Prophylaxis In The City

Locations participating in the Paxlovid USG Patient Assistance Program (PAP) are currently displayed on the new Test-to-Treat locator. Find pharmacies, clinics, and other locations with safe and effective low cost COVID-19 medications.

State and Federal Reporting Requirements

Reporting into Health Partner Ordering Portal (HPOP)
  • Report utilization and doses on hand of USG-distributed Paxlovid and Legevrio at least twice a month by 11:59ET pm on the 15th and last day of the month. Report on hand doses of all other therapeutics once a month by 11:59ET pm the last day of the month.
  • Providers are expected to provide reporting of all USG-distributed courses that they received and should report inventory, administration/dispensing, and disposal data until the provider’s USG product inventory is fully reconciled.
  • USG supply used to support the Paxlovid USG PAP program is not subject to provider agreement reporting requirements.
  • Sites may voluntarily upload commercially acquired inventory data for Paxlovid, Lagevrio, and outpatient Veklury via HPOP. HPOP users can leverage their existing accounts to report, while non-HPOP users can report using the HPOP volunteer reporting website.
  • When reporting utilization of each product, report the quantity used since the last report. Do not report the cumulative amount over time​​​
Click here or more information on HPOP reporting. For any issues related to ordering or reporting of HPOP therapeutics, reach out to HPOP.Support@hhs.gov or 833-748-1979

Provider Resource Library and Other Useful Links

Shelf life Extensions

Shelf-Life Extension infomation. Click the links to view the affected lot numbers.

New! Searchable database of COVID-19 Therapeutic Product Expiration Dates is now available
 
Access COVID-19 Antivirals for Free or at a Reduced Cost
On Nov. 1, 2023, Paxlovid and Lagevrio became commercially available. Patient assistance programs that help pay for these drugs are available to people who are underinsured, uninsured, or publicly insured through Medicaid, Medicare or other programs. See Sample Antiviral Access Programs

TREAT COVID-19

The Chicago Department of Health has partnered with the Chicago Internal Medicine Practice and Research (CIMPAR S.C.) for the TREAT COVID-19 program. CIMPAR S.C. will provide onsite mobile treatment and infection prevention services to LTCF residents of Medicare/Medicaid certified nursing homes and assisted living facilities who test positive for Covid-19.  See flyer for details